References
1. Jossen J, Chu J, Hotchkiss H, et al. Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review. Pediatr Transplant. 2015;19(2):235-243.
2. Deyrup AT, Lee VK, Hill CE, et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients.Am J Surg Pathol. 2006;30(1):75-82.
3. Jonigk D, Laenger F, Maegel L, et al. Molecular and clinicopathological analysis of Epstein-Barr virus-associated posttransplant smooth muscle tumors. Am J Transplant. 2012;12(7):1908-1917.
4. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med.1995;332(1):19-25.
5. Rougemont AL, Alfieri C, Fabre M, et al. Atypical Epstein-Barr virus (EBV) latent protein expression in EBV-associated smooth muscle tumours occurring in paediatric transplant recipients. Histopathology. 2008;53(3):363-367.
6. Liu Y, Chintalapati S, Dietz R, Raza AS, Wang J. EBV-associated hepatic smooth muscle tumor of uncertain biologic behavior after heart transplantation in a pediatric patient: case report. J Gastrointest Oncol. 2017;8(1):E21-E25.
7. Tan CS, Loh HL, Foo MW, Choong LH, Wong KS, Kee TY. Epstein-Barr virus-associated smooth muscle tumors after kidney transplantation: treatment and outcomes in a single center.Clin Transplant. 2013;27(4):E462-468.
8. Stubbins RJ, Alami Laroussi N, Peters AC, et al. Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literature. Transpl Infect Dis.2019;21(1):e13010.
9. Penney SW, Bishop BN, Howell DL. Treatment response with sirolimus for a pediatric patient with an EBV-associated smooth-muscle tumor after bone marrow transplantation.Pediatr Blood Cancer. 2019;66(5):e27585.
10. Twombley K, Pokala H, Ardura MI, et al. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant.2012;16(6):E201-209.
11. Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.The Journal of Clinical Investigation. 2020;130(2):733-747.
12. Hirama T, Tikkanen J, Pal P, Cleary S, Binnie M. Epstein-Barr virus-associated smooth muscle tumors after lung transplantation. Transpl Infect Dis.2019;21(3):e13068.
13. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.Leuk Lymphoma. 2008;49 Suppl 1:27-34.
14. Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett.2015;369(1):37-44.
15. Dipchand AI. Current state of pediatric cardiac transplantation. Ann Cardiothorac Surg.2018;7(1):31-55.